Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07024953 · ClinicalTrials.gov registry record · NA
The Agenda-Setting for Kidney Disease Trial
A NA study, sponsored by Dartmouth-Hitchcock Medical Center.
- Not yet
- Registry status
- NA
- Development phase
- 108
- Enrollment target
NCT07024953: Clinical Trial NA study, sponsored by Dartmouth-Hitchcock Medical Center.
NCT07024953 is a NA study that has not yet begun recruiting, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 108 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07024953, a NA study, has not yet begun recruiting, sponsored by Dartmouth-Hitchcock Medical Center.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 108 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if a tool with a list of discussion topics, called a structured clinical visit agenda-setting intervention (SAS), works for people with advanced chronic kidney disease (CKD) who receive care at a clinic that serves people who live in rural areas. The SAS is called CKD Topics. The researchers will compare the SAS intervention to usual care (the way clinicians usually practice) to see how well it works for people with advanced CKD. This is a special type of clinical trial called a stepped wedge randomized clinical trial (RCT). In this type of trial, every participant will get to experience both usual care and CKD Topics, but for different amounts of time. The researchers will learn if doing a clinical trial of CKD Topics is possible (feasible) and get information about how well CKD Topics helps people with advanced CKD shape visit discussions (self-advocacy) in their appointments with their clinicians. The information the researchers collect in this trial will help design a future trial with more participants. The main questions the researchers aim to answer are: * Is it possible to conduct this type of study of a SAS intervention? i.e. feasibility * Does the SAS intervention help people with advanced CKD shape discussions (self-advocacy) with their clinicians? If so, how much? i.e. preliminary efficacy
Primary Outcome
The primary outcome will be feasibility, assessed by the proportion of patients who received the intervention.
Interventions
- OTHER Chronic Kidney Disease Structured Agenda-Setting Tool
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2028-12 |
| Phase | NA |
What is known before NCT07024953 opens enrollment
NCT07024953 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Chronic Kidney Disease Structured Agenda-Setting Tool is the first listed.
NCT07024953 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07024953 about?
NCT07024953 is a clinical study titled "The Agenda-Setting for Kidney Disease Trial". The goal of this clinical trial is to learn if a tool with a list of discussion topics, called a structured clinical visit agenda-setting intervention (SAS), works for people with advanced chronic kidney disease (CKD) who receive care at a clinic that serves people who live in rural areas. The SAS i...
What is the current status of trial NCT07024953?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 108 participants. The study started on 2026-09-01. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07024953?
The interventions under investigation include: Chronic Kidney Disease Structured Agenda-Setting Tool (OTHER).
Who is sponsoring clinical trial NCT07024953?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07024953's enrollment target sits among peer trials
108 825th of 2000 higher than 1,171 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI